Skip navigation

Please use this identifier to cite or link to this item:
Title: Compression-Induced Phase Transitions of Bicalutamide
Authors: Szafraniec-Szczęsny, Joanna
Antosik-Rogóż, Agata
Knapik-Kowalczuk, Justyna
Kurek, Mateusz
Szefer, Ewa
Gawlak, Karolina
Chmiel, Krzysztof
Peralta, Sebastian
Niwiński, Krzysztof
Pielichowski, Krzysztof
Paluch, Marian
Jachowicz, Renata
Keywords: amorphous solid dispersions; physical stability; bicalutamide; Kollidon®VA64; dissolution; compression
Issue Date: 2020
Citation: Pharmaceutics, Vol. 12, iss 5 (2020), art. no 438
Abstract: The formation of solid dispersions with the amorphous drug dispersed in the polymeric matrix improves the dissolution characteristics of poorly soluble drugs. Although they provide an improved absorption after oral administration, the recrystallization, which can occur upon absorption of moisture or during solidification and other formulation stages, serves as a major challenge. This work aims at understanding the amorphization-recrystallization changes of bicalutamide. Amorphous solid dispersions with poly(vinylpyrrolidone-co-vinyl acetate) (PVP/VA) were obtained by either ball milling or spray drying. The applied processes led to drug amorphization as confirmed using X-ray diffraction and differential scanning calorimetry. Due to a high propensity towards mechanical activation, the changes of the crystal structure of physical blends of active pharmaceutical ingredient (API) and polymer upon pressure were also examined. The compression led to drug amorphization or transition from form I to form II polymorph, depending on the composition and applied force. The formation of hydrogen bonds confirmed using infrared spectroscopy and high miscibility of drug and polymer determined using nonisothermal dielectric measurements contributed to the high stability of amorphous solid dispersions. They exhibited improved wettability and dissolution enhanced by 2.5- to 11-fold in comparison with the crystalline drug. The drug remained amorphous upon compression when the content of PVP/VA in solid dispersions exceeded 20% or 33%, in the case of spray-dried and milled systems, respectively.
DOI: 10.3390/pharmaceutics12050438
ISSN: 1999-4923
Appears in Collections:Artykuły (WNŚiT)

Files in This Item:
File Description SizeFormat 
Szafraniec_Szczesny_Compression_Induced_Phase.pdf3,78 MBAdobe PDFView/Open
Show full item record

Uznanie Autorstwa 3.0 Polska Creative Commons License Creative Commons